Is diabetes drugmaker Amylin (AMLN) close to bankruptcy, as suggested recently by The Business Insider? The short answer is no. The long answer is ... it's actually possible, if everything that ...

Amylin Pharmaceuticals and Eli Lilly had a broad presence at the 70th annual American Diabetes Association convention held in late June. Clinical data presented at the conference for their once ...

According to the American Diabetes Association, 23.6 million children and adults in the U.S., or 7.8% of the population, have diabetes, with 1.6 million new cases diagnosed in people aged 20 years ...

Amylin Pharmaceuticals and Eli Lilly today said their diabetes drug Byetta worked better at reducing blood-sugar levels following a meal compared with Merck's Januvia. The results, based on a a ...

Amylin Pharmaceuticals Inc. suffered a setback Wednesday when the Food and Drug Administration said it wouldn’t approve the company’s experimental diabetes drug without additional information ...

Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and ...

Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine ...

Amylin shares are up 120% over the past year and up 21% year-to-date, closing Tuesday at $48.13. The company has a market capitalization of just under $6 billion and brought in $290 million in ...

Amylin Pharmaceuticals Inc. of San Diego said it had submitted new information to the Food and Drug Administration about Symlin in its 17-year quest to market the experimental injectable drug for ...

BOSTON (MarketWatch) -- Shares of Amylin Pharmaceuticals, Alkermes Inc. and Eli Lilly & Co. all moved higher Tuesday as they reported that their jointly developed diabetes drug can help patients ...